Pipeline
Candidate
- Discovery
- ADME/PoC
- IND Enabling
- Phase 1
- Phase 2
ER+/HER2- Breast Cancer
Oral Selective Estrogen Receptor Degrader targeting Estrogen Receptor (ER) Breast Cancer
Cervical Cancer, H&N Cancer
siRNA drug targeting Human Papilloma Virus (HPV) mediated cancers
NSCLC, Pancreas Cancer
siRNA drug targeting Phosphomevalonate kinase (PMVK) for Radio-Sensitizer
Idiopathic Pulmonary, Fibrosis
Small-molecule targeting SERTA domain-containing protein 1 (SERTAD1) for colorectal cancer
Oral Selective Estrogen Receptor Degrader targeting Estrogen Receptor (ER) Breast Cancer
siRNA drug targeting Human Papilloma Virus (HPV) mediated cancers
siRNA drug targeting Phosphomevalonate kinase (PMVK) for Radio-Sensitizer
Small-molecule targeting SERTA domain-containing protein 1 (SERTAD1) for colorectal cancer
Technology
LNP for mRNA based vaccine, siRNA therapeutics, Therapeutic protein replacement, Genome editing and Cell engineering
LNP for mRNA based vaccine, siRNA therapeutics, Therapeutic protein replacement, Genome editing and Cell engineering
EnhancedBio Inc. | Room 708~711, 7F, KM Tower, 95, Gasan digital 2-ro, Geumcheon-gu, Seoul, Rep.Korea 08505 TEL +82. 2. 867. 6123 | FAX +82. 2. 867. 6129 | E-mail info@enhancedbio.com
COPYRIGHT © EnhancedBio Inc. ALL RIGHTS RESERVED.